Cambridge University wants rights to the intellectual property generated by its staff. The idea has divided scientists in a university well known for its high-tech spin-outs.

"Anything that won't sell, I don't want to invent. Its sale is proof of utility, and utility is success." Thomas A. Edison (1847-1931).

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.

A new Swedish company backed by government and business angels aims to create an entire funding ecosystem for young companies until they become ready for venture capital.

A British pharmaceutical distributor, Beckpharma Ltd., said it licensed two Cuban healthcare products to sell in Europe as part of a broader effort for trade links.

Venture capital’s refusal to continue support helped Cyan Technology into liquidation. Rebuilt by its management, Cyan is now wary of asking VCs for money.

Some strange new ways of raising money are starting to emerge - but would-be borrowers and lenders are still making sense of them.